İnsan papilloma virüsü

BOZDAYI, Gülendam; Alp, Gulcin

İnsan papilloma virüsü

GÜLÇİN ALP AVCI, (Hitit Üniversitesi, Sağlık Yüksekokulu, Çorum, Türkiye)

Gülendam BOZDAYI (Gazi Üniversitesi, Tıp Fakültesi, Tıbbi Mikrobiyoloji Anabilim Dalı, Ankara, Türkiye)

Kafkas Tıp Bilimleri Dergisi

19 3

Yıl: 2013 Cilt: 3 Sayı: 3 Sayfa Aralığı: 136 - 144 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

İnsan papilloma virüsü

Öz:

İnsan Papilloma Virüsü (HPV), zarfı olmayan, sferik protein kapside sahip ve çift sarmallı DNA tașıyan bir virüstür. Fonksiyonel olarak aktif erken ve geç proteinler, erken (E) ve geç (L) gen bölgelerin- den olușturulur. Viral integrasyon tipik olarak E1 ve E2 bölgelerin- de meydana gelmektedir. E6 proteininin hücresel P53 proteinine; E7 proteininin ise Rb proteinine bağlanarak onkogenez mekaniz- masında rol aldığı bilinmektedir. HPV, sadece cinsel yolla değil, aynı zamanda kontamine yüzeylerle indirekt, ciltteki lezyonlarla direkt olarak da bulașabilmektedir. En sık cinsel yolla bulașmakta olup, serviks kanseri dıșındaki malignensilerde de gözlenmektedir. Günümüzde serviks kanseri için majör etken olarak kabul edilen HPV tanısı oldukça önemlidir. Serviks kanseri, “önlenebilir” bir kan- ser tipi olması sebebiyle diğer kanser türlerinden ayırt edilebilmek- tedir. Bu nedenle HPV ile ilișkili enfeksiyonlarda özellikle tarama, erken teșhis ve tedavi büyük öneme sahiptir.

Anahtar Kelime:

Konular: Genel ve Dahili Tıp

Human papillomavirus

Öz:

Human papillomavirus (HPV) is a double-stranded DNA virus with a spheric protein capsid and without an envelope. Functionally ac- tive early and late proteins are created from regions of early and late gene. Typically viral entegration occur in E1 and E2 regions. It is known that the connections of HPV E6 protein to cellular pro- tein p53 and E7 protein to Rb protein play a role in oncogenesis mechanism. Besides its sexual transmission, HPV can be transmit- ted by direct or indirect contact with the skin lesions. It is more often transmitted with sexual intercourse, and is also associated with malignancies other than cervical cancer. Currently, the de- termination of HPV infection which is a major contributing factor for cervical cancer is very important. In comparison with other ma- lignancies, cervical cancer is preventable. Thus, screening, early diagnosis and treatment of lesions associated with HPV infection has a paramount importance.

Anahtar Kelime:

Konular: Genel ve Dahili Tıp

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-27.
2. zur Hausen H. Papıllomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2:342-50.
3. Ramael M, Gudleviciene Z, Didziapetriene J. Natural history and biological behaviour of human papillomavirus: implications for cervical cancer screening. ACTA Med Lituanica 2004; 11: 1-7.
4. De Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology 2004; 324: 17-27.
5. Münger K, Baldwin A, Edwards KM et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol 2004; 78: 11451-60.
6. Dehn D, Torkko KC, Shroyer KR. Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma. Cancer 2007; 111: 1-12.
7. Motoyama S, Ladınes-Llave, Luis Villanueva S et al. The role of human papilloma virus in the molecular biology of cervical carcinogenesis. Kobe J Med Sci 2004; 50: 9-19.
8. Alp Avcı G. İnsan Papillomavirusunun Genomik Yapısı ve Proteinleri. Mikrobiyol Bul 2012; 46: 507-15.
9. Zheng ZM, Baker CC. Papillomavirus genome structure, expression, and post-transcritional regulation. Front Biosci 2006; 11: 2286–302.
10. Howley PM. The molecular biology of papillomavirus transformation. Warner-Lambert Parke-Davis Award Lecture. Am J Pathol 1983; 113: 414-21.
11. Kadaja M, Isok-Paas H, Laos T, et al. Mechanism of genomic instability in cells infected with the high-risk human papillomaviruses. PLOS Pathog 2009; 5: e1000397.
12. Fehrmann F, Laimonis LA. Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation. Oncogene 2003; 22: 5201–7.
13. Yim EK, Park JS. The role of HPV E6 and E7 oncoproteins in HPV- associated cervical carcinogenesis. Cancer Res Treat 2005; 37: 319-24.
14. Kubbutat MH, Vousden KH. Role of E6 and E7 oncoproteins in HPV- induced anogenital malignancies. Sem Virol 1996; 7: 295-304.
15. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci 2006;110: 525-41.
16. Fertey J, Ammermann I, Winkler M, et al. Interaction of the papillomavirus E8-E2C protein with the cellular CHD6 protein contributes to transcriptional repression. J Virol 2010; 84: 9505-15.
17. Stubenrauch F, Zobel T, Iftner T. The E8 domain confers a novel long-distance transcriptional repression activity on the E8E2C protein of high-risk human papillomavirus type 31. J Virol 2001; 75: 4139–49.
18. Thomison J, Thomas LK, Shroyer KR. Human papillomavirus: molecular and cytologic/histologic aspects related to cervical intraepithelial neoplasia and carcinoma. Hum Pathol 2008; 39: 154-66.
19. Palefsky JM, Holly EA. Molecular virology and epidemiology of human papillomavirus and cervical cancer. Cancer Epidemiol Blomarkers Prev 1995; 4: 415-28.
20. Doorbar J. The papillomavirus life cycle. J Clin Virol 2005; 32: 7–15.
21. Milde-Langosch K, Riethdorf S, Löning T, et al. Association of human papillomavirus infection with carcinoma of the cervix uteri and its precursor lesions: theoretical and practical implications. Virchows Arch 2000; 437: 227-33.
22. Stanley MA, Pett MR, Coleman N. HPV: from infection to cancer. Biochem Soc Trans 2007; 35: 1456-60.
23. Moscicki AB. Impact of HPV infection in adolescent populations. J Adolesc Health 2005; 37: S3–9.
24. Bosch FX, de Sanjose S, Castellsague X. Understanding the origin of cervical cancer. In: Prediville W, Davies P. editors. The Health Professional’s HPV Handbook. UK: Taylor and Francis Group; 2004: 41-54.
25. Cruickshank ME. The role of human papillomavirus in risk management. RevGynecol Pract 2003; 3: 229-33.
26. Moscicki AB, Hills N, Shiboski S et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001; 285, 2995–3002.
27. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244–65.
28. Munger K. The role of human papillomaviruses in human cancers. Front Biosci 2002; 7: d641–9.
29. Castle PE, Solomon D, Schiffman M, et al. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 2005; 97: 1066–71.
30. Khan M J, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97(: 1072–9.
31. Gichangi P, Estambale B, Bwayo J, et al. Knowledge and practice about cervical cancer and pap smear testing among patients at Ketyatta National Hospital, Nairobi, Kenya. Int J Gynaecol Cancer 2003;13: 827–33.
32. Zarakolu IP. Cinsel yolla bulaşan infeksiyonlar. Hacettepe Tıp Dergisi 2006; 37: 24-8.
33. Scott M, Nakagawa M, Moscicki B. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol 2001;8209–20.
34. İyibozkurt AC, Berkman S. HPV testleri ve HPV tespitinde yeni yöntemler. Türkiye Klinikleri Jinekoloji ve Obstetrik dergisi 2009; 2: 38-41.
35. Bradley J, Barone TM, Mahe C, et al. Delivering cervical cancer prevention services in low-resource setting. Int J Gynaecol Obstet 2005; 89: 21-29.
36. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003; 16: 1-17.
37. Stoler MH. Human papillomaviruses and cervical neoplasia: a model for carcinogenesis. Int J Gynecol Pathol 2000; 19: 16- 28.
38. Cuzick J, Arbyn M, Sankanarayanan R, et al. Overview of human papilloma virus based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008; 26: 29-41.
39. Castro W, Gage J, Gaffikin L, et al. Effectiveness, safety, and acceptability of cryotherapy: a systematic literature review. Cervical cancer prevention issues in depth 1. Alliance for Cervical Cancer Prevention 2003; 16-30.
40. Luciani S, Gonzales M, Munoz S, et al. Effectiveness of cryotherapy treatment for cervical intraepithelial neoplasia. Int J Gynaecol Obstet 2008; 101: 172–7.
41. Ortaç UF, Ozpak E. Serviksin preinvaziv hastalığı. In: Ayhan A. editör. Klinik Jinekolojik Onkoloji. 6. Baskı. Ankara: Güneş Kitabevi; 2003:p.1-33.
42. Kanser Erken Teşhis, Tarama ve Eğitim Merkezi. URL: http://www.ketem.org/hangi_tarama.php. May 15.2011.
43. Jacob M, Broekhuizen FF, Castro W, et al. Experience using cryotherapy for treatment of cervical precancerous lesions in low-resource settings. Int J Gynaecol Obstet 2005; 89: S13-20.
44. Andersen ES, Thorup K, Larsen G. The results of cryosurgery for cervical intraepithelial neoplasia. Gynecol Oncol 1988; 30: 21 –5.
45. Kobayashi A, Greenblatt RM, Anastos K, et al. Functional attributes of mucosal immunity in cervical intra epitelial neoplasia and effect of HIV infection. Cancer 2004; 64: 6766- 74.
46. Varnai AD, Bollmann B, Bankfalvi A, et al. Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: diagnostic and prognostic implications. Oncol Rep 2008; 19: 457-65.
47. Schiller JT, Douglas R. Lowy Journal of the National Cancer Institute Monographs 2000; 28: 50-54.
48. Galani E, Christodoulou C. Human papillomaviruses and cancer in the post-vaccine. Clin Microbiol Infect 2009; 15: 977–81.
49. Ault KA. Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomized clinical trials. Lancet 2007; 369: 1861-8. 50. Stanley M. Immunobiology of HPV and HPV vaccines. Gynecol Oncol 2008; 109: 15-21.
51. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003; 9: 37–48.
52. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4,5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367:1247–55.
53. Bozon M. Sexuality, gender, and the couple: a sociohistorical perspective. Annu Rev Sex Res 2001; 12: 1–32.
54. Harper DM. Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757–65.
55. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915–27.

APA	Alp G, BOZDAYI G (2013). İnsan papilloma virüsü. , 136 - 144.
Chicago	Alp Gulcin,BOZDAYI Gülendam İnsan papilloma virüsü. (2013): 136 - 144.
MLA	Alp Gulcin,BOZDAYI Gülendam İnsan papilloma virüsü. , 2013, ss.136 - 144.
AMA	Alp G,BOZDAYI G İnsan papilloma virüsü. . 2013; 136 - 144.
Vancouver	Alp G,BOZDAYI G İnsan papilloma virüsü. . 2013; 136 - 144.
IEEE	Alp G,BOZDAYI G "İnsan papilloma virüsü." , ss.136 - 144, 2013.
ISNAD	Alp, Gulcin - BOZDAYI, Gülendam. "İnsan papilloma virüsü". (2013), 136-144.

APA	Alp G, BOZDAYI G (2013). İnsan papilloma virüsü. Kafkas Tıp Bilimleri Dergisi, 3(3), 136 - 144.
Chicago	Alp Gulcin,BOZDAYI Gülendam İnsan papilloma virüsü. Kafkas Tıp Bilimleri Dergisi 3, no.3 (2013): 136 - 144.
MLA	Alp Gulcin,BOZDAYI Gülendam İnsan papilloma virüsü. Kafkas Tıp Bilimleri Dergisi, vol.3, no.3, 2013, ss.136 - 144.
AMA	Alp G,BOZDAYI G İnsan papilloma virüsü. Kafkas Tıp Bilimleri Dergisi. 2013; 3(3): 136 - 144.
Vancouver	Alp G,BOZDAYI G İnsan papilloma virüsü. Kafkas Tıp Bilimleri Dergisi. 2013; 3(3): 136 - 144.
IEEE	Alp G,BOZDAYI G "İnsan papilloma virüsü." Kafkas Tıp Bilimleri Dergisi, 3, ss.136 - 144, 2013.
ISNAD	Alp, Gulcin - BOZDAYI, Gülendam. "İnsan papilloma virüsü". Kafkas Tıp Bilimleri Dergisi 3/3 (2013), 136-144.